March 9, 2010
March 9, 2010
March 9, 2010
March 8, 2010
March 8, 2010
 The Hindu | The Ticker Boston Herald ... Idec are suspending experimental rheumatoid arthritis and lupus treatment ocrelizumab after deaths following its use, casting doubt over its future. ... Roche, Biogen Suffer Setback With Experimental Drug Roche, Biogen stop arthritis drug program Roche, Biogen Halt Ocrelizumab Treatment |
No Survival Improvement in RA MedPage Today Despite decades of dramatic advances in treatment of rheumatoid arthritis, survival has not improved for these patients, a Dutch study found. ... |
A Majestic Research Study Finds Actemra Will Steal Share in the Rheumatoid ... Earthtimes (press release) ... Actemra & the Biologics Market, Majestic Research found that there is a sizeable position for Actemra in the rheumatoid arthritis treatment paradigm. ... |
Roche suspends RA treatment after deaths Reuters O) are suspending rheumatoid arthritis and lupus treatment Ocrelizumab after it caused deaths, marking the latest setback for Roche's pipeline. ... Roche, Biogen Halt Ocrelizumab Treatment Roche, Biogen Idec Suspend Tests for Arthritis Drug Roche, Biogen suspend Ocrelizumab treatment |
AAD: Low Infection Risk Seen with Methotrexate MedPage Today The analysis showed an overall risk of about 2 per 100 patient-years in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis (RA) treated ... |